Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Glaxo-Novartis JV ‘On Track’ To Launch; J&J ‘Well Through’ Most Of OTC Remediation

This article was originally published in The Tan Sheet

Executive Summary

Glaxo’s consumer product sales will be around 25% of the $40 billion total annual revenues the firm projects following the closure of its Novartis agreement. J&J CEO Alex Gorsky sees light at the end of the tunnel for remediation of the firm’s OTC manufacturing under a consent decree with FDA.


Related Content


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts